Mitogen-activated protein kinase pathway inhibitors: Inhibitors for diseases?

被引:0
|
作者
Wang X. [1 ,2 ]
Gong X.-W. [2 ]
Li Y.-H. [1 ]
Jiang Y. [2 ]
机构
[1] College of Life Science, Northeast Forestry University
[2] Key Laboratory of Functional Proteomics of Guangdong Province, Department of Pathophysiology, Southern Medical University
来源
Frontiers of Medicine in China | 2010年 / 4卷 / 1期
基金
中国国家自然科学基金;
关键词
Disease; Drug target; Inhibitor; Mitogen-activated protein kinase; Signal transduction;
D O I
10.1007/s11684-010-0010-0
中图分类号
学科分类号
摘要
Mitogen-activated protein kinase (MAPK) signaling pathway, one of the most important signaling pathways in eukaryotic organism, is involved in multiple cellular events such as cell growth, differentiation, and apoptosis. MAPK is of great importance to the normal function of organisms, while its dysfunction results in various diseases. So far, inhibitors specifically against each subfamilies of MAP kinase have been developed, while more endeavors are needed to discover the compounds selectively targeting a particular subfamily member. Most of the kinase inhibitors exert their functions in an ATP-competitive way or a non-ATP-competitive way. Further studies on the effective mechanism of the MAPK inhibitors and their therapeutic roles in the treatment of diseases are helpful for the illumination of MAP kinase function, the development of novel inhibitors, and the therapy of diseases caused by the dysfunction of the MAPK pathway. © 2010 Higher Education Press and Springer Berlin Heidelberg.
引用
收藏
页码:46 / 53
页数:7
相关论文
共 50 条
  • [31] Implementation of high-content assay for inhibitors of mitogen-activated protein kinase phosphatases
    Vogt, Andreas
    Lazo, John S.
    METHODS, 2007, 42 (03) : 268 - 277
  • [32] Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway (vol 60, pg 143, 2001)
    Yu, C
    Wang, S
    Dent, P
    Grant, S
    MOLECULAR PHARMACOLOGY, 2001, 60 (02) : 403 - 403
  • [33] In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors
    Skobeleva, Natalia
    Menon, Sanjay
    Weber, Lutz
    Golemis, Erica A.
    Khazak, Vladimir
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (03) : 898 - 906
  • [34] Mitogen-activated protein kinase phosphatase: a negative regulator of the mitogen-activated protein kinase cascade
    Haneda, M
    Sugimoto, T
    Kikkawa, R
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 365 (01) : 1 - 7
  • [35] Inhibitors of the mitogen-activated protein kinase kinase 1/2 signaling pathway clear prion-infected cells from PrPSc
    Nordström, EK
    Luhr, KM
    Ibáñez, C
    Kristensson, K
    JOURNAL OF NEUROSCIENCE, 2005, 25 (37): : 8451 - 8456
  • [36] Dehydroeplandrosterone negatively regulates the p38 mitogen-activated protein kinase pathway by a novel mitogen-activated protein kinase phosphatase
    Ashida, K
    Goto, K
    Zhao, Y
    Okabe, T
    Yanase, T
    Takayanagi, R
    Nomura, M
    Nawata, H
    BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 2005, 1728 (1-2): : 84 - 94
  • [37] Combination therapies with mitogen-activated protein kinase kinase inhibitors and immune checkpoint inhibitors in non-small cell lung cancer
    Xu Jia-Li
    Wang Xin-Zhu
    Jiang Hu-Ning
    Chen Yi
    Wang Rong
    Shu Yong-Qian
    中华医学杂志(英文版), 2020, 133 (20) : 2495 - 2497
  • [38] Combination therapies with mitogen-activated protein kinase kinase inhibitors and immune checkpoint inhibitors in non-small cell lung cancer
    Xu, Jia-Li
    Wang, Xin-Zhu
    Jiang, Hu-Ning
    Chen, Yi
    Wang, Rong
    Shu, Yong-Qian
    CHINESE MEDICAL JOURNAL, 2020, 133 (20) : 2495 - 2497
  • [39] Down-regulation of p38 mitogen-activated protein kinase activation and proinflammatory cytokine production by mitogen-activated protein kinase inhibitors in inflammatory bowel disease
    Docena, G.
    Rovedatti, L.
    Kruidenier, L.
    Fanning, A.
    Leakey, N. A. B.
    Knowles, C. H.
    Lee, K.
    Shanahan, F.
    Nally, K.
    McLean, P. G.
    Di Sabatino, A.
    MacDonald, T. T.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2010, 162 (01): : 108 - 115
  • [40] Mitogen-Activated Protein Kinase Pathway in Amyotrophic Lateral Sclerosis
    Sahana, T. G.
    Zhang, Ke
    BIOMEDICINES, 2021, 9 (08)